125 related articles for article (PubMed ID: 22658364)
41. Expression levels of cellular inhibitor of apoptosis proteins and colitogenic cytokines are inversely correlated with the activation of interferon regulatory factor 4.
Masaki S; Watanabe T; Arai Y; Sekai I; Hara A; Kurimoto M; Otsuka Y; Masuta Y; Yoshikawa T; Takada R; Kamata K; Minaga K; Yamashita K; Kudo M
Clin Exp Immunol; 2022 May; 207(3):340-350. PubMed ID: 35553628
[TBL] [Abstract][Full Text] [Related]
42. Development of a peptide-based inducer of nuclear receptors degradation.
Demizu Y; Ohoka N; Nagakubo T; Yamashita H; Misawa T; Okuhira K; Naito M; Kurihara M
Bioorg Med Chem Lett; 2016 Jun; 26(11):2655-8. PubMed ID: 27086122
[TBL] [Abstract][Full Text] [Related]
43. SNIPERs-Hijacking IAP activity to induce protein degradation.
Naito M; Ohoka N; Shibata N
Drug Discov Today Technol; 2019 Apr; 31():35-42. PubMed ID: 31200857
[TBL] [Abstract][Full Text] [Related]
44. IAPs on the move: role of inhibitors of apoptosis proteins in cell migration.
Oberoi-Khanuja TK; Murali A; Rajalingam K
Cell Death Dis; 2013 Sep; 4(9):e784. PubMed ID: 24008728
[TBL] [Abstract][Full Text] [Related]
45. cIAP2 supports viability of mice lacking cIAP1 and XIAP.
Heard KN; Bertrand MJ; Barker PA
EMBO J; 2015 Oct; 34(19):2393-5. PubMed ID: 26427758
[No Abstract] [Full Text] [Related]
46. Protocols for Synthesis of SNIPERs and the Methods to Evaluate the Anticancer Effects.
Tsukumo Y; Tsuji G; Yokoo H; Shibata N; Ohoka N; Demizu Y; Naito M
Methods Mol Biol; 2021; 2365():331-347. PubMed ID: 34432253
[TBL] [Abstract][Full Text] [Related]
47. Correction to: Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.
Cheng L; Zhou Z; Flesken-Nikitin A; Toshkov IA; Wang W; Camps J; Ried T; Nikitin AY
Oncogene; 2021 Mar; 40(9):1754. PubMed ID: 33510357
[No Abstract] [Full Text] [Related]
48. Correction: cIAP1 promotes proliferation and migration and prevents apoptosis in gallbladder cancer in vitro.
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 31015321
[No Abstract] [Full Text] [Related]
49.
Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
[TBL] [Abstract][Full Text] [Related]
50. Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules.
Okuhira K; Shoda T; Omura R; Ohoka N; Hattori T; Shibata N; Demizu Y; Sugihara R; Ichino A; Kawahara H; Itoh Y; Ishikawa M; Hashimoto Y; Kurihara M; Itoh S; Saito H; Naito M
Mol Pharmacol; 2017 Mar; 91(3):159-166. PubMed ID: 27965304
[TBL] [Abstract][Full Text] [Related]
51. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.
Krönke J; Fink EC; Hollenbach PW; MacBeth KJ; Hurst SN; Udeshi ND; Chamberlain PP; Mani DR; Man HW; Gandhi AK; Svinkina T; Schneider RK; McConkey M; Järås M; Griffiths E; Wetzler M; Bullinger L; Cathers BE; Carr SA; Chopra R; Ebert BL
Nature; 2015 Jul; 523(7559):183-188. PubMed ID: 26131937
[TBL] [Abstract][Full Text] [Related]
52. Catalytic in vivo protein knockdown by small-molecule PROTACs.
Bondeson DP; Mares A; Smith IE; Ko E; Campos S; Miah AH; Mulholland KE; Routly N; Buckley DL; Gustafson JL; Zinn N; Grandi P; Shimamura S; Bergamini G; Faelth-Savitski M; Bantscheff M; Cox C; Gordon DA; Willard RR; Flanagan JJ; Casillas LN; Votta BJ; den Besten W; Famm K; Kruidenier L; Carter PS; Harling JD; Churcher I; Crews CM
Nat Chem Biol; 2015 Aug; 11(8):611-7. PubMed ID: 26075522
[TBL] [Abstract][Full Text] [Related]
53. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
[TBL] [Abstract][Full Text] [Related]
54. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling.
Yamanaka S; Sato Y; Oikawa D; Goto E; Fukai S; Tokunaga F; Takahashi H; Sawasaki T
Biochem Biophys Res Commun; 2020 Mar; 524(1):1-7. PubMed ID: 31898971
[TBL] [Abstract][Full Text] [Related]
55. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
[TBL] [Abstract][Full Text] [Related]
56. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
57. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
[TBL] [Abstract][Full Text] [Related]
58. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
Wang M; Lu J; Wang M; Yang CY; Wang S
J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
[TBL] [Abstract][Full Text] [Related]
59. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1.
Cheng B; Ren Y; Cao H; Chen J
Eur J Med Chem; 2020 Aug; 199():112377. PubMed ID: 32388281
[TBL] [Abstract][Full Text] [Related]
60. Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs.
Gabizon R; Shraga A; Gehrtz P; Livnah E; Shorer Y; Gurwicz N; Avram L; Unger T; Aharoni H; Albeck S; Brandis A; Shulman Z; Katz BZ; Herishanu Y; London N
J Am Chem Soc; 2020 Jul; 142(27):11734-11742. PubMed ID: 32369353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
